These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6314397)

  • 21. Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test.
    Moss DE; Johnson RL
    Eur J Pharmacol; 1980 Feb; 61(3):313-5. PubMed ID: 6244965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of delta 9-tetrahydrocannabinol on the morphine-induced hyperactivity of mice.
    Ulkü E; Ayhan IH; Tulunay FC; Uran B; Kaymakçalan S
    Psychopharmacology (Berl); 1980; 69(2):201-5. PubMed ID: 6256790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
    Smith PB; Welch SP; Martin BR
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice.
    Watanabe K; Yamamoto I; Oguri K; Yoshimura H
    Drug Metab Dispos; 1981; 9(3):261-4. PubMed ID: 6113937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-tolerance development to the prolongation of pentobarbitone-induced sleep by delta 8-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice.
    Watanabe K; Narimatsu S; Yamamoto I; Yoshimura H
    J Pharm Pharmacol; 1987 Nov; 39(11):945-7. PubMed ID: 2892923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lethal effects of delta9-tetrahydrocannabinol in mice enhanced by pretreatment with SKF 525-A or chloramphenicol.
    Sofia RD
    Eur J Pharmacol; 1974 May; 26(2):383-5. PubMed ID: 4854932
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of ouabain and digitoxin on hexobarbitone sleeping time in the mouse.
    Doggett NS
    Psychopharmacologia; 1975; 41(3):305-8. PubMed ID: 1153616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration of delta 9-tetrahydrocannabinol-induced teratogenicity by stimulation and inhibition of its metabolism.
    Harbison RD; Mantilla-Plata B; Lubin DJ
    J Pharmacol Exp Ther; 1977 Aug; 202(2):455-65. PubMed ID: 886474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and pharmacological activity of a phosphate ester of delta8-tetrahydrocannabinol.
    Yoshimura H; Watanabe K; Oguri K; Fujiwara M; Ueki S
    J Med Chem; 1978 Oct; 21(10):1079-81. PubMed ID: 569207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of delta-9-tetrahydrocannabinol on barbiturate withdrawal convulsions in the rat.
    Gildea ML; Bourn WM
    Life Sci; 1977 Sep; 21(6):829-32. PubMed ID: 562463
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats.
    Tseng AH; Harding JW; Craft RM
    Behav Brain Res; 2004 Sep; 154(1):77-83. PubMed ID: 15302113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of tolerance to pethidine in rats, pretreated or not, with beta-naphtoflavone or SKF 525 A.
    Cenajek D; Szczawińska K; Chodera A; Nowakowska E
    Acta Physiol Pol; 1988; 39(4):281-7. PubMed ID: 3252692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic disposition of 8 alpha, 9 alpha- and 8 beta, 9 beta-epoxyhexahydrocannabinols in the mouse.
    Narimatsu S; Watanabe K; Shimonishi T; Matsubara K; Yamamoto I; Yoshimura H
    J Pharmacobiodyn; 1984 Sep; 7(9):671-6. PubMed ID: 6098641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
    Williams J; Haller VL; Stevens DL; Welch SP
    Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on some aspects of the neuropharmacology of butylurea.
    Dar MS; Fakouhi T
    Arch Int Pharmacodyn Ther; 1974 Apr; 208(2):204-12. PubMed ID: 4854473
    [No Abstract]   [Full Text] [Related]  

  • 36. Interactions of tricyclic antidepressants and barbiturates in barbiturate-tolerant and nontolerant rats.
    Liu SJ; Huang CL; Waters IW
    J Pharmacol Exp Ther; 1975 Aug; 194(2):285-95. PubMed ID: 1151759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hyaluronidase and sleep].
    Safta L; Cuparencu B; Mierut G; Zillmann J
    Anesth Analg (Paris); 1972; 29(1):52-7. PubMed ID: 5069152
    [No Abstract]   [Full Text] [Related]  

  • 38. beta-Diethylaminoethyldiphenylpropylacetate (SKF 525-A) and 2,4-dichloro-6-phenylphenoxyethylamine.HBr (DPEA) inhibition of fatty acid conjugation to 11-hydroxy-delta 9-tetrahydrocannabinol by the rat liver microsomal system.
    Leighty EG
    Biochem Pharmacol; 1980 Apr; 29(7):1071-3. PubMed ID: 6248072
    [No Abstract]   [Full Text] [Related]  

  • 39. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine.
    Roberts JD; Gennings C; Shih M
    Eur J Pharmacol; 2006 Jan; 530(1-2):54-8. PubMed ID: 16375890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.